GlobeNewswire·Jan 8, 2026, 8:30 AM ET

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

RenovoRx announced new pharmacokinetic & pharmacodynamic data from a sub-study of its Phase III TIGeR-PaC trial to be presented at ASCO GI 2026 in San Francisco.
The sub-study led by Dr. Paula M. Novelli evaluated 16 patients across six sites, comparing intra-arterial gemcitabine (IAG) using the TAMP platform against standard intravenous gemcitabine.
Results showed IAG administration reduced systemic gemcitabine levels & increased inactive metabolite levels compared to IV treatment.
A direct correlation was observed between increased metabolite levels & reduced CA 19-9 biomarkers, suggesting potential for improved chemotherapy response.
The targeted delivery approach aims to increase local drug potency while decreasing systemic side effects common in pancreatic cancer treatment.
RenovoRx reported approximately $900,000 in RenovoCath device revenues for the first nine months of 2025 following initial commercial orders received in December 2024.
The TIGeR-PaC trial is ongoing to determine if IAG improves overall survival & reduces side effects versus the current standard of care for locally advanced pancreatic cancer.
The IAG combination product has received Orphan Drug Designation for pancreatic & bile duct cancer, granting seven years of market exclusivity upon FDA approval.
RenovoRx is actively commercializing the FDA-cleared RenovoCath device while IAG remains under investigation via an investigational new drug application.